News

Apple Faces Struggles as Analysts Downgrade Stock Rating

Apple Faces Struggles as Analysts Downgrade Stock Rating

Apple Stock Rating Downgraded by Jefferies Analysts

In an unexpected turn of events, Jefferies analysts have revised their stock rating for Apple Inc (NASDAQ: AAPL) from Hold to Underperform. This decision signals a growing concern regarding the tech company’s upcoming fiscal first quarter report. Analysts foresee Apple missing both its earnings and guidance targets, leading to a decline in share value. On the announcement, Apple’s stock experienced a slight dip of around 1% in premarket trading.

Adjustments to Price Target

Analysts have also slashed their price target on Apple shares from $211.84 to $200.75, indicating a potential downside of 13% from the recent closing price. This caution reflects a broader trend of disappointing sales, particularly focusing on the iPhone segment. Weak performance in iPhone sales, particularly for the new iPhone 17 and 18 models, raises alarms among investors.

Weak iPhone Sales Impacting Outlook

As highlighted in their report, Jefferies analysts attribute their bearish expectations to a variety of factors, including weaker than anticipated iPhone sales. They project that Apple will not only fall short of its anticipated 5% revenue growth for the first quarter but will also provide a modest forecast for the subsequent quarter, suggesting only low single-digit revenue growth.

Revised Forecasts and Shipment Projections

The analysts have adjusted their forecast for iPhone shipments from a previously expected growth of 1% to an anticipated decline of 2%. Data from the International Data Corporation (IDC) indicates that iPhone shipments may have decreased by approximately 4% year-over-year in this timeframe. This shift is supported by alarming trends in China, where iPhone sell-through during the quarter reportedly plummeted.

Impacts on Other Apple Products

Not only are iPhone sales under scrutiny but the conditions for other Apple products such as iPads and MacBooks are also gloomy. The overall sluggishness in consumer electronics has contributed to this challenging landscape. The downgrade alerts investors to the potential disappointment regarding future earnings guidance for the March quarter, further compounded by new policy changes affecting government subsidies in key markets such as China.

Concerns Over New Models

Jefferies analysts also express skepticism about the upcoming SE4 iPhone model, suggesting that it might not meet market expectations. They believe the competition for the SE4 will primarily come from used models of iPhone 13 and 14 rather than Android devices or newer iPhone versions. According to the team, Apple’s focus on integrating AI into smartphones may not draw consumer interest, particularly in the Chinese market.

Near-Term AI Outlook in Smartphones

The team at Jefferies underscores that the near-term prospects for AI features in smartphones are less optimistic than anticipated. A survey reveals that many US consumers find AI functionalities in smartphones to be lacking in usefulness. There are also concerns regarding potential delays in Apple’s advanced packaging roadmap, necessary for enhancing AI capabilities in upcoming devices.

Future Earnings Forecast Reduction

In light of these troubling indicators, Jefferies has revised its earnings per share (EPS) forecasts for Apple downwards by 2% for the upcoming three years. The EPS estimates for fiscal year 2025 (FY25) and fiscal year 2026 (FY26) now sit about 4% below consensus, contributing further to a cautious sentiment among investors. Analysts warn that even with new iPhone form factors expected over the next two years, volume growth might remain tepid if AI advancements take longer than projected to become impactful.

Frequently Asked Questions

What prompted Jefferies to downgrade Apple's stock rating?

Jefferies downgraded Apple’s stock due to expectations of missed earnings and guidance targets, primarily driven by weaker iPhone sales.

What is the new price target set for Apple stock by Jefferies?

Jefferies has reduced the price target for Apple stock to $200.75 from $211.84.

How do analysts view the outlook for future iPhone sales?

Analysts project a decline in iPhone shipments, with expectations of a 2% decrease in fiscal year 2025, reflecting current market trends.

What are the concerns regarding the SE4 iPhone model?

Analysts question the demand for the SE4 model, suggesting it will mainly compete with older iPhone models rather than new devices.

What is the impact of AI on Apple's future?

The near-term outlook for AI capabilities in smartphones appears subdued, with consumers not finding current AI features particularly beneficial.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
Join the Class Action Against Red Cat Holdings, Inc. Today

Updated Category News Views 185

Understanding the Class Action Against Red Cat Holdings, Inc. Red Cat Holdings, Inc. is currently under the spotlight due to a class action securities lawsuit filed by the law firm Levi & Korsinsky, LLP. The firm is reaching out to investors who believe they have incurred losses due to the alleged securities fraud that transpired between a specified period. If you have...

Continue Reading
GRAIL Initiates Patient Testing with Innovative Blood Test for Lung Cancer

Updated Category News Views 127

GRAIL Announces Milestone in Lung Cancer Detection GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare firm focused on early cancer detection, has achieved a significant milestone by announcing that the first patient has been assessed for eligibility through its innovative non-small cell lung cancer (NSCLC) ctDNA Assay. This groundbreaking development occurs within the...

Continue Reading
Neurocrine Biosciences Enhances Collaboration with Takeda

Updated Category News Views 197

Neurocrine Biosciences Enhances Collaboration with Takeda Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has recently announced an amendment to strengthen the strategic collaboration with Takeda. This partnership focuses on the development and commercialization of osavampator, an innovative therapeutic candidate that holds promise for patients suffering from major depressive...

Continue Reading
LivaNova Prepares to Reveal 2024 Year-End Financials

Updated Category News Views 94

LivaNova's Upcoming Financial Announcement LivaNova PLC (Nasdaq: LIVN), a prominent player in the medical technology sector, is gearing up for an important event. The company will hold a conference call in which they will discuss their financial results from the fourth quarter as well as the entire year of 2024. This event is slated for a Tuesday afternoon and is expected...

Continue Reading